HomeCompareCDTX vs ORCC

CDTX vs ORCC: Dividend Comparison 2026

CDTX yields 0.90% · ORCC yields 9.79%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ORCC wins by $451.00 in total portfolio value
10 years
CDTX
CDTX
● Live price
0.90%
Share price
$221.38
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$21.0K
Annual income
$95.80
Full CDTX calculator →
ORCC
ORCC
● Live price
9.79%
Share price
$13.48
Annual div
$1.32
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$21.4K
Annual income
$1.04
Full ORCC calculator →

Portfolio growth — CDTX vs ORCC

📍 ORCC pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCDTXORCC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CDTX + ORCC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CDTX pays
ORCC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CDTX
Annual income on $10K today (after 15% tax)
$76.79/yr
After 10yr DRIP, annual income (after tax)
$81.43/yr
ORCC
Annual income on $10K today (after 15% tax)
$832.34/yr
After 10yr DRIP, annual income (after tax)
$0.88/yr
At 15% tax rate, CDTX beats the other by $80.55/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CDTX + ORCC for your $10,000?

CDTX: 50%ORCC: 50%
100% ORCC50/50100% CDTX
Portfolio after 10yr
$21.2K
Annual income
$48.42/yr
Blended yield
0.23%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on CDTX right now

CDTX
Analyst Ratings
1
Strong
7
Buy
3
Hold
Consensus: Buy
Price Target
$181.50
-18.0% upside vs current
Range: $150.00 — $221.50
Altman Z
32.6
Piotroski
2/9
ORCC
Analyst Ratings
9
Buy
4
Hold
1
Sell
Consensus: Buy
Price Target
$16.00
+18.7% upside vs current
Range: $16.00 — $16.00
Altman Z
0.5
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CDTX buys
0
ORCC buys
0
No recent congressional trades found for CDTX or ORCC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCDTXORCC
Forward yield0.90%9.79%
Annual dividend / share$2.00$1.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%-50%
Portfolio after 10y$21.0K$21.4K
Annual income after 10y$95.80$1.04
Total dividends collected$933.00$1.0K
Payment frequencyquarterlyquarterly
SectorStockBDC
Analyst consensusBuyBuy
Analyst price target$181.50$16.00

Year-by-year: CDTX vs ORCC ($10,000, DRIP)

YearCDTX PortfolioCDTX Income/yrORCC PortfolioORCC Income/yrGap
1← crossover$10,790$90.34$11,190$489.61$400.00ORCC
2$11,637$91.11$12,229$256.01$592.00ORCC
3$12,543$91.82$13,216$130.74$673.00ORCC
4$13,514$92.50$14,207$66.02$693.00ORCC
5$14,553$93.14$15,234$33.17$681.00ORCC
6$15,665$93.74$16,317$16.62$652.00ORCC
7$16,856$94.30$17,468$8.32$612.00ORCC
8$18,131$94.83$18,695$4.16$564.00ORCC
9$19,495$95.33$20,006$2.08$511.00ORCC
10$20,956$95.80$21,407$1.04$451.00ORCC

CDTX vs ORCC: Complete Analysis 2026

CDTXStock

Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also advances its Cloudbreak platform to develop conjugates for the prevention and treatment of influenza and other viral infections, such as RSV, HIV, and the SARS-CoV-2 strains causing COVID-19. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. Cidara Therapeutics, Inc. was incorporated in 2012 and is based in San Diego, California.

Full CDTX Calculator →

ORCCBDC

Owl Rock Capital Corporation is a business development company. The fund makes investments in senior secured or unsecured loans, subordinated loans or mezzanine loans and also considers equity-related securities including warrants and preferred stocks also pursues preferred equity investments and common equity investments. Within private equity, it seeks to invest in growth, acquisitions, market or product expansion, refinancings and recapitalizations. It seeks to invest in middle market companies based in the United States, with EBITDA between $10 million and $250 million annually and/or annual revenue of $50 million and $2.5 billion at the time of investment.

Full ORCC Calculator →
📬

Get this CDTX vs ORCC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CDTX vs SCHDCDTX vs JEPICDTX vs OCDTX vs KOCDTX vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.